Next Phase Newsletter

A VC fund in the USA is independently managed in a strategic partnership with a large corporation. The firm invests in early-stage disruptive life science tools, therapeutics, and diagnostic companies. Typical allocations range from $2-10 million initially in a Series A or B round and can be up to $15-20 million over the life span of the company. The firm seeks to syndicate with other leading institutional and strategic investors.  The firm expects to make 4-5 new investments over the next 12 months and considers opportunities globally with a focus in the US.

The firm is interested in areas where its expertise and special relationship with the parent corporation can add value. This includes therapeutics, clinical diagnostics, and life science tools. The firm focuses on applications of genomics including sequencing, assay development, agriculture and environmental science, industrial biotech, digital health, public safety and personal wellness, proteomics and other ‘omics’ areas. The firm prefers pre-revenue companies that have achieved proof-of-concept.

The firm seeks to work with experienced management teams with sector expertise. The firm’s team members have decades of entrepreneurial experience in genomics and may request a board seat depending on the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Western Europe currently manages two funds. The firm typically makes equity investments into life science companies at preclinical and clinical stages. The investment size is up to €2.5 million. The firm generally makes 1-3 allocations per year. The firm focuses on companies that are based in the Netherlands and Belgium.

The firm is currently looking for new investment opportunities in Therapeutics, Diagnostics and Medical Devices spaces. The firm is very opportunistic in terms of subsectors and it is interested in Medical Products in the broad sense. The firm also has no restrictions in terms of indications; however, it is most interested in companies with potential for real benefit and/or potential to save healthcare costs. The firm also consider orphan drugs if the business case is good. Historically, the firm was active in medical technology companies developing imaging, surgical instruments and single use devices. The firm was also active in therapeutics and diagnostics companies specializing in drug delivery, biomarker and vaccines.

The firm focuses on investments in private companies and it will consider pre-revenue companies. The firm has no specific requirements for companies’ management team, revenue or EBITDA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The fund is the corporate venture capital arm of a global science-based company active in health, nutrition and materials. The firm makes equity investments into seed and venture stage companies generally taking less than 25% ownership. The firm makes allocations ranging from a few hundred thousand dollars to $5 million initially with additional capital held for future financing rounds. The firm is looking to make approximately 5-10 investments over the next 6-9 months with +10 being made over the next 2 years. The firm invests in companies located around the globe with a focus on the U.S., Europe and Israel.

Where it comes to Biomedical, the firm is looking for materials science companies in orthopedics and soft tissue repair. The firm also actively invests in human nutritional health, with a specific focus on companies active in personalized nutrition, and companies developing nutritional products. While the firm has invested in companies all the way from seed to PIPE, they generally invest into companies that have products in development or early stage commercialization.

The firm highly values experience in a firm’s management team and generally looks to take a board seat and play an active role in its portfolio companies. The firm is looking for companies that are interested in cooperation/alignment with relevant parent company businesses.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The company is a NASDAQ-listed company that acquires, develops and commercializes promising drugs and technologies by forming and financing subsidiary companies. All subsidiary companies have access to resources necessary for cultivating and maintaining their business such as scientific, clinical, regulatory, manufacturing, legal and financial expertise. Among these key resources are committed investment capital, experienced start-up management with in-house Entrepreneurs in Residence (EIRs), world-class scientific expertise, and shared facilities. The company does not make equity only investments, but is open to a variety of deal structures to license, co-develop or acquire assets, including traditional milestone-based licensing deals, joint ventures, and option agreements with equity arrangements.

The company focuses primarily on therapeutic opportunities, but will also consider drug delivery devices/technologies. Current areas of interest include: – Late clinical stage or marketed dermatology programs/products – IND ready, clinical or marketed rare disease, oncology, neurology, opthamology, GI or Hepatology

The firm has no management team requirements and will work with entrepreneurs of all experience levels coming from academia or industry, and has no restriction on the geographic location of companies or technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The fund is a venture capital with offices in Massachusetts and California with approximately $1.8 billion under management. The firm is currently investing out of their third fund, a $825M fund that closed in the summer of 2021. The firm will make equity investments of approximately $40–60 million across all stages of private financing and can either lead investments or co-invest. The firm considers investment opportunities worldwide.

The firm invests primarily in therapeutics and invests broadly across different therapeutic areas and modalities. Areas of high interest include precision medicine approaches, gene therapy, autoimmune diseases, oncology, neurology (particularly diseases with genetically defined populations), ophthalmology, and rare diseases. The firm generally invests from preclinical (2–3 years pre-IND) through to Phase II, and prefers to invest in assets with good animal models and/or genetic evidence to support efficacy and target validation.

The firm generally invests in privately held companies and likes to work with experienced management teams who have had prior startup successes. The firm is an active investor and the partners have deep experience in company building, and we are therefore interested in providing support on strategy, BD, recruiting and other areas of active management in addition to providing capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A life sciences venture capital fund founded in 2014 with an office in Central, Hong Kong is currently managing two funds with $330 million assets under management and is actively seeking investment opportunities. On average, the size of investment is $5-25M in venture rounds. The firm prefers to act as the lead investor but is also open to co-investing. The firm looks for companies located around the globe, with a preference in the US and China. The firm is actively seeking new investment opportunities.

The firm is focused on Therapeutics and Medical Devices opportunities. The firm’s core focused therapeutic areas include oncology, immunology and CNS diseases, but is also opportunistic in other indications (modality agnostic) and willing to consider orphan indications. The firm is also interested in interventional, novel medical devices in cardiovascular, neuro-vascular diseases.

The firm prefers management team with strong scientific background and expertise, successful track records would be a plus but is not required. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A venture capital group based out of Boston seeks to make seed and venture equity investments in early stage digital health related companies, focusing on Seed to Series A rounds. The firm is recently making a transition into digital health with their new fund. The firm typically allocates between $100k-$500k USD in their initial investment, but has the capability to invest large amounts as well (their LPs put in $40Million USD as a follow on to one of their investments). The firm also has the option of making follow-on investments and for companies they think would do well in China, has many resources in China that they can leverage for portfolio companies interested in operating in China. The firm is geographically agnostic, but prefers to invest in companies that are based in the US.

The firm is looking for companies in the digital health space or technologies that utilize/integrate software, AI, big data, virtual reality, or analytics within the healthcare field. The firm prefers companies that don’t have to go through regulatory hurdles. In terms of indication, the firm is agnostic so long as there is a basis in digital health. However, the firm currently has a particular interest in senior care related technologies given the recent need in China.

The firm prefers companies and teams with strong science behind their technology. They prefer, but do not require companies that have an interest in working in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.